Latest Health Technology at CES 2021
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Prior to pregnancy, her viral load had been undetectable for more than 2 years.
Positive topline results were announced from the phase 3 SPIRIT 1 study investigating relugolix (Myovant Sciences), in combination with estradiol and norethindrone acetate, in women with pain associated with endometriosis.
The novel combined oral contraceptive pill includes estetrol 15mg (E4) and drospirenone 3mg (DRSP).
Testosterone only recommended for postmenopausal women with hypoactive sexual desire dysfunction
Some excess risk persists for >10 years after ceasing therapy; magnitude varies with duration of use
According to the findings of a recent retrospective analysis, pregnancy and pregnancy-related adverse events related to isotretinoin administration have dropped since the initiation of the iPLEDGE program by the Food and Drug Administration (FDA) in 2006, however reports of fetal exposure persist. The iPLEDGE program is a Risk Evaluation and Mitigation Strategy (REMS) that aims…
Teen, adult women, including pregnant women, should be assessed for anxiety as part of routine care
Previous Phase 2 studies confirmed esterol has minimal impact on liver cells and metabolic pathways, as well as on coagulation parameters.
The expanded approval was based on safety and efficacy data from a confirmatory Phase 3 randomized, double-blind, placebo-controlled multicenter study evaluating Osphena in patients with moderate to severe vaginal dryness.